Biomarin Pharmaceutical Inc., of San Rafael, Calif., said the European Commission (EC) granted marketing authorization for Brineura (cerliponase alfa) for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 deficiency.